Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPY1R | P25929 | 1/20 | 0.46 |
| ▸ | NPY2R | P49146 | 1/20 | 0.46 |
| ▸ | SCD | O00767 | 3/20 | 0.45 |
| ▸ | HRH1 | P35367 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 3/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5467688 | 0.98 | DRD2 (0.45) | DRD2DRD3SMN1; SMN2KDM4ENPY1R | |
| SCHEMBL5467987 | 0.92 | HTR2C (0.50) | SMN1; SMN2ALDH1A1HTR2CHTR2BSLC6A4 | |
| Hydrochloric Acid SCHEMBL5473725 | 0.91 | HTR2C (0.49) | HTR2CHTR2BSLC6A4HTR6 | |
| SCHEMBL5685983 | 0.88 | SRC (0.46) | SMN1; SMN2HRH1EGFRERBB2SRC | |
| SCHEMBL10274504 | 0.87 | SCD (0.56) | SMN1; SMN2KDM4ENPY1RNPY2RSCD | |
| SCHEMBL22278139 | 0.84 | EGFR (0.47) | SMN1; SMN2KDM4ENPY1RNPY2RHRH1 | |
| SCHEMBL22278146 | 0.84 | EGFR (0.50) | DRD2SMN1; SMN2KDM4ENPY1RNPY2R | |
| SCHEMBL1178126 | 0.79 | SLC6A3 (0.55) | DRD2DRD3SMN1; SMN2HRH1HTR2C | |
| SCHEMBL1178129 | 0.79 | SLC6A3 (0.55) | DRD2DRD3SMN1; SMN2HRH1HTR2C | |
| SCHEMBL12676933 | 0.79 | HRH1 (0.47) | SMN1; SMN2KDM4ENPY1RNPY2RHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021404-A1 | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2007-01-25 | — | — | US | claimed |
| EP-1638939-A2 | AZA-RING DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-03-29 | — | — | EP | claimed |
| WO-2004113297-A2 | AZA-RING DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2004-12-29 | — | — | WO | claimed |
| WO-2021097240-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2020154571-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-20070021404-A1 | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021404-A1 | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | DRD2 36/4885DRD3 99/4885SMN1; SMN2 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.